Skip to content

At-home Monitoring of patients during Chemoradiation for Oesophageal canceR: the AMCOR trial

At-home Monitoring of patients during Chemoradiation for Oesophageal canceR: the AMCOR trial - the AMCOR trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53606
Enrollment
30
Registered
2022-12-28
Start date
2025-05-15
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oesophageal cancer

Interventions

Participants will measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature. Once a week a finger stick test will be performed by the participant.

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 at the time of signing informed consent. 2. Histologically proven adenocarcinoma, squamous cell carcinoma or mixed type of the oesophagus or gastro-oesophageal junction. 3. Indication for definitive or neoadjuvant CRT, with chemotherapy that consists of weekly carboplatin/paclitaxel. 4. Written, informed consent. 5. Ability to comply with all protocol required actions (at home measurements are done individually by the participant him- or herself).

Exclusion criteria

Exclusion criteria: 1. Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or the carrying out of the measurements at home.

Design outcomes

Primary

MeasureTime frame
At least 80% of participants complete at least 80% of predefined at home measurements.

Secondary

MeasureTime frame
n.a.

Countries

Netherlands

Contacts

Public ContactR.S.N. Fehrmann

Universitair Medisch Centrum Groningen

r.s.n.fehrmann@umcg.nl050-3612821

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)